Bio Medica Laboratories came to market through an SME IPO that opened on 21 May 2026 and closed on 25 May 2026, and the shares listed on 29 May 2026 on NSE SME. The price band was ₹132 to ₹139 per share and one lot was 1000 shares, so the minimum application was ₹1,39,000. The issue size was ₹52.43 crore. It combined a fresh issue of new shares with an offer for sale by existing shareholders.
Skyline Financial Services Private Ltd was the registrar to the issue, and Narnolia Financial Services Ltd was the lead manager.
As of 25 May 2026.
| Day |
|---|
| 1 |
| 2 |
| 3 |
The Bio Medica Laboratories deals in the manufacture of parenteral formulations that involve the development and supply of ethical drug products, generics, and over-the-counter drugs in liquid and dry powder forms for injection purposes. Product Portfolio: 58 products are present in liquid injectable forms Dry powder injectable form of products is also supplied with 15 such products It supplies various types of products like generic drugs, proprietary drugs, over the counter drugs, and others. Business Model:
The Bio Medica Laboratories function as a business to business organization dealing only in contract manufacturing of its products. It develops formulations of different products as per the requirements of various organizations. It is licensed for good manufacturing practices (GMP) and good laboratory practices (GLP) as certified by the Food & Drugs Administration, Madhya Pradesh. Manufacturing plants: Two plants are located in Indore district of Madhya Pradesh.
As described in the offer document.
| Metric | 30-Nov-25 | 31-Mar-25 | 31-Mar-24 | 31-Mar-23 |
|---|
Mr. Mukesh Mehta, Mr. Pradeep Mehta.
Work out the listing gain for this SME IPO
If the retail portion is not fully subscribed, every valid application is allotted in full. If it is oversubscribed, SEBI's rules require that as many applicants as possible receive at least one lot, so the shares are allotted by a computerised lottery across all valid applications, one lot each, until the retail portion is exhausted. Applying for more lots does not improve your chance in a lottery; it only increases what you receive if the issue is under-subscribed.
The basis of allotment document, published by the registrar on the allotment date, states the ratio: for example, one applicant in seven received one lot.
Allotment status is published by the registrar on its website, searchable by PAN, application number or demat account, and also on the exchange's website. Allotted shares are credited to the demat account the day before listing, and blocked money for unsuccessful applications is released the same day. The Rupix app can check allotment status by PAN once the registrar publishes it.
Shares list within three working days of the issue closing. On listing day the exchanges run a special pre-open session from nine o'clock, during which orders are collected and an opening price is discovered from them; trading in the share begins after that, usually around ten. The opening price is the listing price that appears on this page once the issue has listed, and the listing gain or loss is the difference between it and the issue price.
For a mainboard issue, the share then trades in the normal way with the exchange's price band for a new listing. For an SME issue, shares trade in lots rather than one at a time, and the market can be thin, so selling on listing day is not always possible at the opening price. Capital gains on shares sold within a year of allotment are short-term and taxed at the short-term rate.
Bio Medica Laboratories IPO was a ₹52.43 crore book-built issue, comprising a fresh issue of ₹47.19 crore and an offer for sale of ₹5.24 crore. It was priced at ₹132–₹139 per share with a lot size of 1,000 shares; the minimum retail application was 2,000 shares (₹2,78,000). The IPO was open from May 21 to May 25, 2026 and was subscribed 2.31x.
Shares listed on NSE SME on May 29, 2026 at ₹111.20, a 20.0% discount to the issue price of ₹139. Skyline Financial Services Pvt. Ltd. is the registrar. Narnolia Financial Services Ltd. is the book running lead manager.
The price band of Bio Medica Laboratories IPO is ₹132 to ₹139 per share.
The lot size of Bio Medica Laboratories IPO is 1000 shares.
The minimum investment for Bio Medica Laboratories IPO is approximately ₹2,78,000 based on the upper price band.
The allotment date of Bio Medica Laboratories IPO is May 26, 2026.
You can check Bio Medica Laboratories IPO allotment status on the registrar or stock exchange websites using your PAN or application number after allotment. You can also check the Bio Medica Laboratories IPO allotment status on Rupix for quick and easy access.
₹132 to ₹139 per share, against a face value of ₹10. Most applicants bid at the cut-off price, the top of the band, so that the application was valid whatever price the issuer finally fixed.
One lot was 1000 shares, and every application had to be a whole number of lots. At the top of the band that made the minimum application ₹1,39,000. After listing, SME shares also trade in lots rather than one share at a time.
₹1,39,000, for one lot of 1000 shares at the top of the price band. The amount was blocked in the applicant's bank account through ASBA or a UPI mandate while the issue was open, and released on the allotment date to applicants who were not allotted shares.
It opened on 21 May 2026 and closed on 25 May 2026.
The basis of allotment was published on 26 May 2026 by Skyline Financial Services Private Ltd, and allotted shares were credited to demat accounts before listing.
The shares listed on 29 May 2026 on NSE SME.
The issue size was ₹52.43 crore. The fresh issue was 33,95,000 shares (aggregating up to ₹47.19 crore). The offer for sale was 3,77,000 shares (aggregating up to ₹5.24 crore).